18 February 2016
EMA/CAT/82731/2016
Procedure Management and Committees Support Division

Committee for Advanced Therapies (CAT)

Agenda for the meeting on 18-19 February 2016

Chair: Paula Salmikangas - Vice-chair: Martina Schüßler-Lenz

18 February 2016, 09:00 – 18:30, room 03-E
19 February 2016, 09:00 – 15:00, room 03-E

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members, alternates and experts 5

1.2. Adoption of agenda 5

1.3. Adoption of the minutes 5

1.4. Technical information 5

2. Evaluation of ATMPs 5

2.1. Opinions 5

2.2. Oral explanations 5

2.3. Day 180 List of outstanding issues (LoOIs) 5

2.3.1. Autologous CD34+ cells transduced with retroviral vector containing the adenosine deaminase gene; *Orphan*; EMA/H/C/003854 5

2.4. Day 120 Lists of questions (LoQs) 6

2.5. Day 80 assessment reports 6

2.6. Ongoing initial full application 6

2.7. New applications 6

2.8. Withdrawal of initial marketing authorisation application 6

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004 6

2.10. GMP and GCP inspections requests 6

2.11. Type II variations 6

2.12. Other post-authorisation activities 6

2.12.1. Glybera - Alipogene tiparvovec; Orphan; EMEA/H/C/002145/SOB 002.3 6

3. Certification of ATMPs 6

3.1. Opinions 7

3.2. Day 60 evaluation reports 7

3.2.1. C3BS-CQR-1 - Autologous bone marrow-derived mesenchymal stem cells; EMEA/H/C/002832/0004 7

3.3. Ongoing initial application 7

3.4. New applications 7

4. Scientific Recommendation on Classification of ATMPs 7

4.1. New requests – appointment of CAT Co-ordinators 7

4.1.1. Autologous *ex vivo* expanded polyclonal $CD4^{+}CD25^{+}CD127^{lo/-}FOXP3^{+}$ regulatory T cells 7

4.1.2. DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain 7

4.1.3. Autologous stromal vascular fraction 7

4.1.4. Autologous human bone marrow mononuclear cells 8

4.2. Day 30 Co-ordinators' first reports 8

4.2.1. hBEDATCs - Human burn eschar and debrided adipose tissue cells 8
4.2.2. Co-culture of keratinocytes and human burn eschar and debrided adipose tissue cells 8
4.2.3. Recombinant non-replicative serotype 5 human adenovirus containing sequences coding for the core protein, polymerase protein and selected domains of the envelope protein of hepatitis B virus (Genotype D) 8
4.2.4. Irradiated, whole-cell, allogeneic tumour immunotherapy 8
4.2.5. Autologous Epstein-Barr virus specific T-cells derived from peripheral blood mononuclear cells, expanded *ex vivo* 9
4.2.6. Hematopoietic stem and progenitor cells (HSPC) genetically modified with zinc finger nucleases (ZFNs) to disrupt the erythroid enhancer (ENH) of the gene encoding the human transcription factor BCL11A 9
4.3. Day 60 Co-ordinators' revised reports following List of Questions 9
4.3.1. Autologous adipose-derived regenerative cells encapsulated in carboxymethylcellulose – Postponed to March 2016 9
4.3.2. Autologous cells of stromal vascular fraction (SVF) and autologous adipose derived stem cells 9
4.4. Finalisation of procedures 9
4.4.1. Adeno-associated viral vector serotype 2 containing the human *RPE65* gene 9
4.4.2. *Ex vivo* expanded allogeneic human immuno-modulatory progenitor (iMP) cells 10
4.4.3. Human amniotic membrane mesenchymal stem cells 10
4.4.4. Human umbilical cord mesenchymal stem cells 10
4.4.5. Co-culture of keratinocytes and human umbilical cord mesenchymal stem cells 10
4.4.6. Co-culture of keratinocytes and human amniotic membrane mesenchymal stem cells 11
4.4.7. Fibroblasts and keratinocytes co-culture 11
4.5. Follow-ups and guidance 11
5. Scientific Advice 11
5.1. New requests – appointment of CAT Co-ordinators 11
5.2. CAT Rapporteurs' reports 11
5.3. Lists of issues 11
5.4. Finalisation of Scientific Advice procedures 11
6. Pre-Authorisation Activities 11
6.1. Paediatric investigation plans (PIP) 12
6.2. ITF briefing meetings in the field of ATMPs 12
7. Organisational, regulatory and methodological matters 12
7.1. Mandate and organisation of the CAT 12
7.1.1. Strategic Review & Learning meeting 12
7.1.2. Procedural advice on the evaluation of Advanced Therapy Medicinal Products (pre-authorisation, post-authorisation, re-examination); EMEA/630043/2008 12
7.1.3. Plenary meeting timing 12
7.1.4. CAT template documents and procedures 12

7.2. Coordination with EMA Scientific Committees 13
7.2.1. Committee for Medicinal Products for Human Use (CHMP) 13
7.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups 13
7.3.1. EMA/Cancer Drug Development Forum (CDDF) workshop on 4-5 February 2016 on cancer immunotherapy: 'Challenges for the approval of anti-cancer immunotherapeutic drugs' ... 13
7.3.2. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP) 13
7.3.3. Working Party with Patients' and Consumers' Organisations (PCWP) 13
7.4. Co-operation within the EU regulatory network 14
7.4.1. Good manufacturing practice (GMP) requirements for ATMPs 14
7.4.2. European Commission request to address the issue of orphan similarity of ATMPs 14
7.4.3. National requirements for post-licensure for medicinal products containing micro-organisms (GMO)? 14
7.5. Co-operation with international regulators 15
7.5.1. ATMP cluster teleconference with FDA and Health Canada 15
7.6. CAT Work Plan 15
7.7. Planning and reporting 15
7.8. Others 15
7.8.1. Seminar on 12th February 2016 in Budapest on adoptive T-cell immunotherapy 15
8. Any other business 15
9. Explanatory notes 16

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held on 18-19 February 2016. See February 2016 CAT minutes (to be published post March 2016 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 18-19 February 2016

1.3. Adoption of the minutes

CAT minutes of 21-22 January 2016

1.4. Technical information

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 List of outstanding issues (LoOIs)

2.3.1. Strimvelis – Autologous CD34+ cells transduced with retroviral vector containing the adenosine deaminase gene; *Orphan*; EMA/H/C/003854

Treatment of children aged 0-18 diagnosed with ADA-SCID and for whom no suitable HLA-identical sibling bone marrow donor is available

Scope: Day 180 list of outstanding issues

Action: for adoption

Documents:
LoOIs
BWP report

Notes:
September 2015: D120 LoQs adopted
April 2015: CAT granted an accelerated assessment

2.4. Day 120 Lists of questions (LoQs)

No items

2.5. Day 80 assessment reports

No items

2.6. Ongoing initial full application

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations

No items

2.12. Other post-authorisation activities

2.12.1. Glybera - Alipogene tiparvovec; Orphan; EMEA/H/C/002145/SOB 002.4

UniQure Biopharma B.V.

Rapporteur: Christiane Niederlaender; CHMP Coordinators: Greg Markey

Scope: Protocol for the study to measure postprandial chylomicrons.

Action: for adoption

Documents:
Draft Opinion

3. Certification of ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinions

No items

3.2. Day 60 evaluation reports

3.2.1. C3BS-CQR-1 - Autologous bone marrow-derived mesenchymal stem cells; EMEA/H/C/002832/0004

3.3. Ongoing initial application

No items

3.4. New applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – appointment of CAT Co-ordinators

4.1.1. Autologous *ex vivo* expanded polyclonal $CD4^{+}CD25^{+}CD127^{lo/-}FOXP3^{+}$ regulatory T cells

Intended for the treatment of Type 1 Diabetes Mellitus

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received 19th January 2016

4.1.2. DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain

Intended for the treatment of refractory chronic non-infectious uveitis

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received 13th January 2016

4.1.3. Autologous stromal vascular fraction

Intended as an autologous lipofiller

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received 4th February 2016

4.1.4. Autologous human bone marrow mononuclear cells

Intended for the treatment type 2 diabetes mellitus

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
Request received 11th February 2016

4.2. Day 30 Co-ordinators' first reports

4.2.1. hBEDATCs - Human burn eschar and debrided adipose tissue cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-hBEDATCs in suspension
-hBEDATCs as sheet
-hBEDATCs on acellular amniotic matrix
-hBEDATCs on acellular dermal matrix

Action: for adoption

Document:
ATMP classification report

4.2.2. Co-culture of keratinocytes and human burn eschar and debrided adipose tissue cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-hBEDATCs on acellular amniotic matrix
-hBEDATCs on acellular dermal matrix

Action: for adoption

Document:
ATMP classification report

4.2.3. Recombinant non-replicative serotype 5 human adenovirus containing sequences coding for the core protein, polymerase protein and selected domains of the envelope protein of hepatitis B virus (Genotype D)

Intended for the treatment of chronic hepatitis B

Action: for adoption

Document:
ATMP classification report

4.2.4. Irradiated, whole-cell, allogeneic tumour immunotherapy

Intended for the treatment of pancreatic cancer

Action: for adoption

Document:
ATMP classification report

4.2.5. Autologous Epstein-Barr virus specific T-cells derived from peripheral blood mononuclear cells, expanded *ex vivo*

Intended for the treatment of Epstein-Barr Virus (EBV) positive malignancies

Action: for adoption

Document:
ATMP classification report

4.2.6. Hematopoietic stem and progenitor cells (HSPC) genetically modified with zinc finger nucleases (ZFNs) to disrupt the erythroid enhancer (ENH) of the gene encoding the human transcription factor BCL11A

Intended for the treatment of β-thalassemia

Scope: appointment of CAT Co-ordinator and adoption of timetable

Action: for adoption

Document:
ATMP classification report

4.3. Day 60 Co-ordinators' revised reports following List of Questions

4.3.1. Autologous adipose-derived regenerative cells encapsulated in carboxymethylcellulose – Postponed to March 2016

Intended for the treatment of cosmetic dermal filling

Scope: request from the applicant dated 10th February 2016 to a further one-month clock stop

Action: for information

4.3.2. Autologous cells of stromal vascular fraction (SVF) and autologous adipose derived stem cells

Intended for treatment of keloid scars and aging skin

Action: for adoption

Document:
Responses to the LoQs
Revised ATMP classification report

4.4. Finalisation of procedures

4.4.1. Adeno-associated viral vector serotype 2 containing the human *RPE65* gene

Intended for the treatment of inherited retinal degeneration due to autosomal recessive *RPE65* gene mutations

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.4.2. *Ex vivo* expanded allogeneic human immuno-modulatory progenitor (iMP) cells

Intended for the treatment of incomplete revascularisation as an adjunct to CABG in patients with congenital coronary artery malformations

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

See also 5.4.1.

4.4.3. Human amniotic membrane mesenchymal stem cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-hAMMSCs in suspension
-hAMMSCs as sheet
-hAMMSCs seeded on acellular amniotic matrix
-hAMMSCs seeded on acellular dermal matrix

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.4.4. Human umbilical cord mesenchymal stem cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-hUSCs in suspension
-hUSCs as sheet
-hUSCs seeded on acellular amniotic matrix
-hUSCs seeded on acellular dermal matrix

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.4.5. Co-culture of keratinocytes and human umbilical cord mesenchymal stem cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-seeded on acellular amniotic matrix
-seeded on acellular dermal matrix

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.4.6. Co-culture of keratinocytes and human amniotic membrane mesenchymal stem cells

Intended for the treatment of burns and non-healing wounds

Different product formulations:
-seeded on acellular amniotic matrix
-seeded on acellular dermal matrix

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.4.7. Fibroblasts and keratinocytes co-culture

Intended for the treatment of deep and extensive burns, chronic wounds, skin donor sites

Product formulation:
- seeded on transgenic porcine acellular dermal matrix

Action: for information

Document:
ATMP classification report

Note: the European Commission raised no comments

4.5. Follow-ups and guidance

No items

5. Scientific Advice

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Co-ordinators

5.2. CAT Rapporteurs' reports

5.3. Lists of issues

5.4. Finalisation of Scientific Advice procedures

6. Pre-Authorisation Activities

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans (PIP)

6.2. ITF briefing meetings in the field of ATMPs

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Strategic Review & Learning meeting

CAT-PDCO-CTFG joint Strategic Review & Learning meeting will take place in Utrecht, Netherlands on 1st-2nd June 2016 under the auspices of the Dutch Presidency of the Council of the European Union

CAT resources: Hans Ovelgönne

Scope: initial discussion to agree on topics for the agenda. The scientific focus will be on dose finding in the context of extrapolation to children

Action: for discussion

Document**:**
Draft agenda

Note**:** CAT members are asked to send proposals for agenda topics

7.1.2. Procedural advice on the evaluation of Advanced Therapy Medicinal Products (pre-authorisation, post-authorisation, re-examination); EMEA/630043/2008

CAT resources: Paula Salmikangas, Martina Schüßler-Lenz, Marit Hystad

Scope: Update/revision of the document

Action: for discussion and appointment of CAT members to draft the revision

Note: CAT/CHMP adopted the document in March 2009. This guidance describes the procedure for evaluation of ATMPs for initial marketing authorisation and for post-authorisation procedures (e.g. variations, renewal, etc.) detailing the interactions, the roles and responsibilities of the committees involved in the assessment of ATMPs.

7.1.3. Plenary meeting timing

CAT resources: Paula Salmikangas

Scope: request for change in meeting times (from current timing of Thurs 09.00 – Fri 15.00 to new timing of Weds 14.00 - Fri 12.00) to accommodate CAT workload and needs

Action: for discussion

7.1.4. CAT template documents and procedures

CAT resources: Paula Salmikangas

Action: for discussion

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the January 2016 meeting

Action: for information

Documents:
-Summary of Outcomes

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. EMA/Cancer Drug Development Forum (CDDF) workshop on 4-5 February 2016 on cancer immunotherapy: 'Challenges for the approval of anti-cancer immunotherapeutic drugs'

CAT resources: Martina Schüßler-Lenz

Scope: Webinar on Challenges for the approval of anti-cancer immunotherapeutic drugs took place on 4-5 February 2016

Action: for information

7.3.2. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting – 17 September 2015

EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting - Session on communication and information on medicines – 08 March 2016

EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting – 09 March 2016

Report on EMA's workshop on risk minimisation measures - Towards optimising risk minimisation measures – 16 Sept 2015

Action: For information

Document tabled:
Minutes of the PCWP/HCPWP joint meeting – 17 September 2015
Agenda of the PCWP/HCPWP joint meeting – Session on communication and information on medicines - 08 March 2016
Draft Agenda of the PCWP/HCPWP joint meeting – 09 March 2016
Report on EMA's workshop on risk minimisation measures – 16 September 2015

7.3.3. Working Party with Patients' and Consumers' Organisations (PCWP)

EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations – 26 November 2015

Action: For information

Document tabled:
Minutes of the PCWP meeting - 26 November 2015

7.4. Co-operation within the EU regulatory network

7.4.1. Good manufacturing practice (GMP) requirements for ATMPs

CAT drafting group members: Ivana Haunerova, Margarida Menezes-Ferreira, Guido Panté, Ilona Reischl, Paula Salmikangas, Belaid Sekkali, Marcos Timón, Christiane Niederlaender, Jurgen Scherer, M. Hoefnagel

Scope: discussion of the comments received during the external consultation and next steps

Action: for information

Documents:
Agenda
Minutes of the meeting that took place on 16.11.15.
Minutes of the meeting that took place on 30.11.15.
External comments
http://ec.europa.eu/health/files/advtherapies/2015_pc/publ_cons_doc_2015.pdf

7.4.2. Orphan similarity for ATMPs

CAT drafting group: Martina Menezes-Ferreira, Nicolas Ferry, Paula Salmikangas, Ilona Reischl, Christiane Niederlaender, Michele Lipucci;

Scope: Reflection from the perspective of ATMPs on the concept of 'similar active substance' as referred to in Art 3(3)c of Reg (EC) No 847/2000 of April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concept 'similar medicinal product' and 'clinical superiority'

Action: for discussion

Note: virtual meeting took place on 9th February 2016

7.4.3. National requirements for post-licensure for medicinal products containing micro-organisms (GMO)

CAT resources: Ilona Reischl

Scope: National question on GMO issues for licensed medicinal products

Action: for discussion

http://www.epa.ie/pubs/legislation/geneticallymodifiedorganismsgmo/directive200941ec.html

Note: DIR/2009/41/EC article 3, 3) states that:

"This Directive shall not apply to the storage, culture, transport, destruction, disposal or use of GMMs which have been placed on the market in accordance with Directive 2001/18/EC or pursuant to other Community legislation which provides for a specific environmental risk assessment similar to that laid down in that Directive, provided that the contained use is in accordance with the conditions, if any, of the consent for placing on the market."

7.5. Co-operation with international regulators

7.5.1. ATMP cluster teleconference with FDA and Health Canada

The teleconference will take place during the plenary meeting on Thursday 18th February from 14.00hrs – 15.00hrs

CAT resources: Paula Salmikangas

Action: for adoption

Document table:
Agenda

7.6. CAT Work Plan

No items

7.7. Planning and reporting

No items

7.8. Others

7.8.1. Seminar on 12th February 2016 in Budapest on adoptive T-cell immunotherapy

CAT resource: Mikuláš Hrubiško

Scope: oral feedback

Action: for information

8. Any other business

Date of next CAT meeting:
Tuesday 22nd – Wednesday 23rd March 2016

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

DG: Drafting Group

EC: European Commission

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMP: Good Manufacturing Practice

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

PDCO: Paediatric Committee

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee

RP: Reflection paper

RSI: Request for supplementary information

SA: Scientific Advice

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Scientific Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines

that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/